International Journal of Molecular Sciences (2020-09-01)

Prediction Power on Cardiovascular Disease of Neuroimmune Guidance Cues Expression by Peripheral Blood Monocytes Determined by Machine-Learning Methods

  • Huayu Zhang,
  • Edwin O. W. Bredewold,
  • Dianne Vreeken,
  • Jacques. M. G. J. Duijs,
  • Hetty C. de Boer,
  • Adriaan O. Kraaijeveld,
  • J. Wouter Jukema,
  • Nico H. Pijls,
  • Johannes Waltenberger,
  • Erik A.L. Biessen,
  • Eric P. van der Veer,
  • Anton Jan van Zonneveld,
  • Janine M. van Gils

Journal volume & issue
Vol. 21, no. 6364
p. 6364


Read online

Atherosclerosis is the underlying pathology in a major part of cardiovascular disease, the leading cause of mortality in developed countries. The infiltration of monocytes into the vessel walls of large arteries is a key denominator of atherogenesis, making monocytes accountable for the development of atherosclerosis. With the development of high-throughput transcriptome profiling platforms and cytometric methods for circulating cells, it is now feasible to study in-depth the predicted functional change of circulating monocytes reflected by changes of gene expression in certain pathways and correlate the changes to disease outcome. Neuroimmune guidance cues comprise a group of circulating- and cell membrane-associated signaling proteins that are progressively involved in monocyte functions. Here, we employed the CIRCULATING CELLS study cohort to classify cardiovascular disease patients and healthy individuals in relation to their expression of neuroimmune guidance cues in circulating monocytes. To cope with the complexity of human datasets featured by noisy data, nonlinearity and multidimensionality, we assessed various machine-learning methods. Of these, the linear discriminant analysis, Naïve Bayesian model and stochastic gradient boost model yielded perfect or near-perfect sensibility and specificity and revealed that expression levels of the neuroimmune guidance cues SEMA6B, SEMA6D and EPHA2 in circulating monocytes were of predictive values for cardiovascular disease outcome.